Login / Signup

The anticoagulant efficacy of rivaroxaban may be attenuated in cirrhotic patients.

Andrea De GottardiJuan Carlos Garcia-Pagannull null
Published in: Liver international : official journal of the International Association for the Study of the Liver (2018)
Keyphrases
  • end stage renal disease
  • venous thromboembolism
  • atrial fibrillation
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • patient reported outcomes
  • patient reported